The Gastrointestinal Cancer Channel is supported with funding from Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESSO 45 | A multidimensional approach to clinical complete response in rectal cancer
Sara Lonardi, MD, Veneto Institute of Oncology, Padua, Italy, discusses the multidisciplinary approach required for evaluating clinical complete response in rectal cancer, emphasizing that assessment is multidimensional and requires integration of multiple factors. Radiological response from MRI imaging must be combined with digital examination by the surgeon to comprehensively determine whether a patient has achieved clinical complete response. This interview took place at the 2026 European Society of Surgical Oncology (ESSO) Annual Meeting in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yes, clearly the evaluation in rectal cancer is multi-professional. We need a multi… Oh, my God, multidisciplinary team because we need the evaluation of the clinical complete response is multidimensional. We need to put together the radiological response. We need it to put it together. And so surgeons need to be sure that the MRI is not showing a feature of residual disease. But then there is also the digital examination by the surgeon...
Yes, clearly the evaluation in rectal cancer is multi-professional. We need a multi… Oh, my God, multidisciplinary team because we need the evaluation of the clinical complete response is multidimensional. We need to put together the radiological response. We need it to put it together. And so surgeons need to be sure that the MRI is not showing a feature of residual disease. But then there is also the digital examination by the surgeon. There is clearly evaluation of the, I don’t know, tumor marker, tolerability of the treatment. And so it’s a multiple… It’s like putting together a puzzle to REACH to declare that we are facing a clinical complete response and that we can consider an on-operative management.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
